首页 > 最新文献

Lancet Rheumatology最新文献

英文 中文
Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial. 在健康志愿者和类风湿性关节炎患者中评估鞘氨醇-1-磷酸受体-1 的选择性激动剂 proximod:1 期双盲、随机、安慰剂对照、剂量递增试验。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-10-22 DOI: 10.1016/S2665-9913(24)00199-1
Hong Zhang, Qianqian Li, Cuiyun Li, Min Wu, Hong Chen, Yang Li, Feng You, Yanshi Zhao, Jing Jin, Xiaoguang Chen, Yanhua Ding
<p><strong>Background: </strong>Proximod is a selective agonist of sphingosine-1-phosphate receptor-1 (S1PR1). It acts by redirecting lymphocytes from the circulation to secondary lymph nodes, and is under development as an immunomodulator for rheumatoid arthritis. We aimed to evaluate the safety, pharmacokinetics, and preliminary efficacy of proximod in healthy volunteers and patients with rheumatoid arthritis.</p><p><strong>Methods: </strong>We did a two part, phase 1, double-blind, randomised, placebo-controlled, ascending dose trial at a single centre in China. Eligible participants were adults aged 18-50 years with a BMI of 18-28 kg/m<sup>2</sup> for healthy volunteers and aged 18-70 years with a BMI of 18-30 kg/m<sup>2</sup> for patients with rheumatoid arthritis. In part 1, healthy volunteers were randomly assigned within ten cohorts to receive a single oral dose of proximod (0·125 mg, 0·25 mg, 0·5 mg, 1 mg, 1·5 mg, 2 mg, 3 mg, 5 mg, 10 mg, or 15 mg in cohorts 1-10) or placebo. In part 2, healthy volunteers were randomly assigned to receive once-daily doses of proximod 5 mg or placebo, and patients with rheumatoid arthritis were randomly assigned to receive once-daily doses of proximod 5 mg, proximod 10 mg, or placebo, for 28 days. Patients and investigators were masked to treatment assignment. The primary outcomes were safety, tolerability, and pharmacokinetic profile of proximod for 72 days in healthy volunteers and for 48 days in patients with rhematoid arthritis, assessed in all treated participants. This trial is registered with ClinicalTrials.gov (NCT06361199, NCT06361186), and is complete.</p><p><strong>Findings: </strong>Between Nov 1, 2017, and June 22, 2021, 124 healthy volunteers were randomly assigned in part 1 of the study and 124 were included in the analyses (mean age 34·3 years [SD 6·9], 62 [50%] of 124 participants were women and 62 [50%] were men, and 116 [94%] were Han Chinese ethnicity). Between Feb 16, 2022, and Oct 8, 2023, 113 participants were screened for inclusion in part 2 (80 healthy volunteers and 33 patients with rheumatoid arthritis). 79 participants were excluded and 34 were randomly assigned (10 healthy participants and 24 patients with rheumatoid arthritis), 34 of whom were included in the analyses. Ten (100%) of ten healthy participants were Han Chinese ethnicity, with a mean age of 39·9 years (SD 7·3). Five (50%) of ten healthy volunteers were women and five (50%) were men). 22 (92%) of 24 participants with rheumatoid arthritis were Han Chinese ethnicity, with a mean age of 52·7 years (SD 6·8). 22 (92%) of 24 patients with rheumatoid arthritis were women and two (8%) were men. In part 1, all doses of proximod were well tolerated, with no dose-related adverse reactions or serious adverse events observed. In part 2, 74 adverse reactions were reported in eight (80%) of ten healthy volunteers and 22 (92%) of 24 patients with rheumatoid arthritis. Adverse events associated with proximod were predominantly mil
背景Proximod 是鞘氨醇-1-磷酸受体-1(S1PR1)的选择性激动剂。它通过将循环中的淋巴细胞重新导向次级淋巴结而发挥作用,目前正被开发为治疗类风湿性关节炎的免疫调节剂。我们旨在评估 proximod 在健康志愿者和类风湿关节炎患者中的安全性、药代动力学和初步疗效:我们在中国的一个中心进行了一项分为两部分、第一阶段、双盲、随机、安慰剂对照、剂量递增的试验。符合条件的健康志愿者为年龄在 18-50 岁、体重指数在 18-28 kg/m2 的成年人,类风湿关节炎患者为年龄在 18-70 岁、体重指数在 18-30 kg/m2 的成年人。在第 1 部分中,健康志愿者被随机分配到 10 个队列中,接受单次口服剂量的 proximod(在第 1-10 队列中分别为 0-125 毫克、0-25 毫克、0-5 毫克、1 毫克、1-5 毫克、2 毫克、3 毫克、5 毫克、10 毫克或 15 毫克)或安慰剂。在第二部分中,健康志愿者被随机分配接受每日一次剂量的proximod 5毫克或安慰剂,类风湿关节炎患者被随机分配接受每日一次剂量的proximod 5毫克、proximod 10毫克或安慰剂,共28天。患者和研究人员对治疗分配均蒙面。主要结果是对所有接受治疗的参与者评估proximod在健康志愿者体内72天和类风湿关节炎患者体内48天的安全性、耐受性和药代动力学特征。该试验已在ClinicalTrials.gov(NCT06361199、NCT06361186)注册,并已完成。研究结果:2017年11月1日至2021年6月22日期间,124名健康志愿者被随机分配到研究的第一部分,124人被纳入分析(平均年龄34-3岁[SD 6-9],124名参与者中有62名[50%]为女性,62名[50%]为男性,116名[94%]为汉族)。在 2022 年 2 月 16 日至 2023 年 10 月 8 日期间,共筛选出 113 名参与者(80 名健康志愿者和 33 名类风湿性关节炎患者)纳入第 2 部分。79名参与者被排除,34名参与者被随机分配(10名健康参与者和24名类风湿性关节炎患者),其中34人被纳入分析。10 名健康参与者中有 10 人(100%)为汉族,平均年龄为 39-9 岁(SD 7-3)。10 名健康志愿者中有 5 名(50%)为女性,5 名(50%)为男性。)在 24 名类风湿性关节炎患者中,22 人(92%)为汉族,平均年龄为 52-7 岁(标准差为 6-8)。24 名类风湿性关节炎患者中,22 名(92%)为女性,2 名(8%)为男性。在第一部分中,所有剂量的普罗西莫德耐受性良好,未观察到与剂量相关的不良反应或严重不良事件。在第二部分中,10名健康志愿者中有8名(80%)和24名类风湿性关节炎患者中有22名(92%)报告了74例不良反应。与 Proximod 相关的不良反应主要为轻度或中度。在第 2 部分中,接受普罗西莫德治疗的三组患者体内普罗西莫德及其活性代谢物磷酸普罗西莫德的浓度均逐渐升高,5 毫克组和 10 毫克组在第 14 天达到 S1PR1 激动剂对磷酸普罗西莫德的 EC50 值(6-1 毫微克/毫升),10 毫克组在第 7 天达到 EC50 值。在健康志愿者和类风湿性关节炎患者中,5 毫克组在第 28 天对磷酸丙西莫德的平均 Ctrough 值分别为 7-7 纳克/毫升和 10-2 纳克/毫升;在类风湿性关节炎患者中,10 毫克组的平均 Ctrough 值为 15-3 纳克/毫升。在类风湿性关节炎患者中,所有 Proximod 组的淋巴细胞计数在治疗后都有所下降,大约在第 28 天降至最低点,5 毫克组从基线下降的百分比为 65-25%,10 毫克组为 71-64%,安慰剂组为 20-57%:Proximod在28天的治疗期间表现出良好的耐受性,证明了其在降低血液淋巴细胞计数方面的潜力。这些结果凸显了 S1PR1 激动剂 Proximod 作为类风湿关节炎治疗潜在候选药物的前景,值得在后续临床研究中进一步探讨:北京联合制药厂和健宽(苏州)生物技术有限公司。
{"title":"Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial.","authors":"Hong Zhang, Qianqian Li, Cuiyun Li, Min Wu, Hong Chen, Yang Li, Feng You, Yanshi Zhao, Jing Jin, Xiaoguang Chen, Yanhua Ding","doi":"10.1016/S2665-9913(24)00199-1","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00199-1","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Proximod is a selective agonist of sphingosine-1-phosphate receptor-1 (S1PR1). It acts by redirecting lymphocytes from the circulation to secondary lymph nodes, and is under development as an immunomodulator for rheumatoid arthritis. We aimed to evaluate the safety, pharmacokinetics, and preliminary efficacy of proximod in healthy volunteers and patients with rheumatoid arthritis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We did a two part, phase 1, double-blind, randomised, placebo-controlled, ascending dose trial at a single centre in China. Eligible participants were adults aged 18-50 years with a BMI of 18-28 kg/m&lt;sup&gt;2&lt;/sup&gt; for healthy volunteers and aged 18-70 years with a BMI of 18-30 kg/m&lt;sup&gt;2&lt;/sup&gt; for patients with rheumatoid arthritis. In part 1, healthy volunteers were randomly assigned within ten cohorts to receive a single oral dose of proximod (0·125 mg, 0·25 mg, 0·5 mg, 1 mg, 1·5 mg, 2 mg, 3 mg, 5 mg, 10 mg, or 15 mg in cohorts 1-10) or placebo. In part 2, healthy volunteers were randomly assigned to receive once-daily doses of proximod 5 mg or placebo, and patients with rheumatoid arthritis were randomly assigned to receive once-daily doses of proximod 5 mg, proximod 10 mg, or placebo, for 28 days. Patients and investigators were masked to treatment assignment. The primary outcomes were safety, tolerability, and pharmacokinetic profile of proximod for 72 days in healthy volunteers and for 48 days in patients with rhematoid arthritis, assessed in all treated participants. This trial is registered with ClinicalTrials.gov (NCT06361199, NCT06361186), and is complete.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between Nov 1, 2017, and June 22, 2021, 124 healthy volunteers were randomly assigned in part 1 of the study and 124 were included in the analyses (mean age 34·3 years [SD 6·9], 62 [50%] of 124 participants were women and 62 [50%] were men, and 116 [94%] were Han Chinese ethnicity). Between Feb 16, 2022, and Oct 8, 2023, 113 participants were screened for inclusion in part 2 (80 healthy volunteers and 33 patients with rheumatoid arthritis). 79 participants were excluded and 34 were randomly assigned (10 healthy participants and 24 patients with rheumatoid arthritis), 34 of whom were included in the analyses. Ten (100%) of ten healthy participants were Han Chinese ethnicity, with a mean age of 39·9 years (SD 7·3). Five (50%) of ten healthy volunteers were women and five (50%) were men). 22 (92%) of 24 participants with rheumatoid arthritis were Han Chinese ethnicity, with a mean age of 52·7 years (SD 6·8). 22 (92%) of 24 patients with rheumatoid arthritis were women and two (8%) were men. In part 1, all doses of proximod were well tolerated, with no dose-related adverse reactions or serious adverse events observed. In part 2, 74 adverse reactions were reported in eight (80%) of ten healthy volunteers and 22 (92%) of 24 patients with rheumatoid arthritis. Adverse events associated with proximod were predominantly mil","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 2024 US election—voting for equitable health care 2024 年美国大选--为公平的医疗保健投票。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-10-21 DOI: 10.1016/S2665-9913(24)00308-4
The Lancet Rheumatology
{"title":"The 2024 US election—voting for equitable health care","authors":"The Lancet Rheumatology","doi":"10.1016/S2665-9913(24)00308-4","DOIUrl":"10.1016/S2665-9913(24)00308-4","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 11","pages":"Page e733"},"PeriodicalIF":15.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gout in central Asia: a few things make a big difference – Authors' reply 中亚地区的痛风:几件事就能带来巨大变化 - 作者回复。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-10-21 DOI: 10.1016/S2665-9913(24)00281-9
Marita Cross , Kanyin Liane Ong , Hailey Hagins , Ewerton Cousin , Lyn March , Anthony Woolf
{"title":"Gout in central Asia: a few things make a big difference – Authors' reply","authors":"Marita Cross ,&nbsp;Kanyin Liane Ong ,&nbsp;Hailey Hagins ,&nbsp;Ewerton Cousin ,&nbsp;Lyn March ,&nbsp;Anthony Woolf","doi":"10.1016/S2665-9913(24)00281-9","DOIUrl":"10.1016/S2665-9913(24)00281-9","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 11","pages":"Page e748"},"PeriodicalIF":15.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research in Brief 研究简介
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-10-21 DOI: 10.1016/S2665-9913(24)00309-6
Jennifer Thorley
{"title":"Research in Brief","authors":"Jennifer Thorley","doi":"10.1016/S2665-9913(24)00309-6","DOIUrl":"10.1016/S2665-9913(24)00309-6","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 11","pages":"Page e750"},"PeriodicalIF":15.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gout in central Asia: a few things make a big difference 中亚地区的痛风:几件事就能带来很大不同。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-10-21 DOI: 10.1016/S2665-9913(24)00280-7
Chokan Baimukhamedov , Galymzhan Togizbayev
{"title":"Gout in central Asia: a few things make a big difference","authors":"Chokan Baimukhamedov ,&nbsp;Galymzhan Togizbayev","doi":"10.1016/S2665-9913(24)00280-7","DOIUrl":"10.1016/S2665-9913(24)00280-7","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 11","pages":"Pages e747-e748"},"PeriodicalIF":15.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Rheumatol 2024; 6: e664–65 柳叶刀风湿病学》2024;6:e664-65 更正。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-10-21 DOI: 10.1016/S2665-9913(24)00310-2
{"title":"Correction to Lancet Rheumatol 2024; 6: e664–65","authors":"","doi":"10.1016/S2665-9913(24)00310-2","DOIUrl":"10.1016/S2665-9913(24)00310-2","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 11","pages":"Page e749"},"PeriodicalIF":15.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Explanation for substandard of care comparators in rheumatology randomised trial protocols 解释风湿病学随机试验方案中未达到标准的护理比较对象。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-10-21 DOI: 10.1016/S2665-9913(24)00277-7
Jacky Sheng , Andrew Zhang , Hannah Moyer , Marie Hudson , Glen Hazlewood , Vibeke Strand , Jonathan Kimmelman
{"title":"Explanation for substandard of care comparators in rheumatology randomised trial protocols","authors":"Jacky Sheng ,&nbsp;Andrew Zhang ,&nbsp;Hannah Moyer ,&nbsp;Marie Hudson ,&nbsp;Glen Hazlewood ,&nbsp;Vibeke Strand ,&nbsp;Jonathan Kimmelman","doi":"10.1016/S2665-9913(24)00277-7","DOIUrl":"10.1016/S2665-9913(24)00277-7","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 11","pages":"Pages e743-e745"},"PeriodicalIF":15.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing personalised precision treatment for Still's disease based on molecular characteristics and disease progression. 根据分子特征和疾病进展,推进斯蒂尔病的个性化精准治疗。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-10-18 DOI: 10.1016/S2665-9913(24)00225-X
Yujie Shen, Jinchao Jia, Jialin Teng, Chengde Yang, Qiongyi Hu

Still's disease, a systemic autoinflammatory disorder with a classic multigenetic background, is characterised by polyarthritis, high-spiking fever, salmon-like evanescent skin rash, and hyperferritinaemia. Although the exact cause of Still's disease remains unclear, it is believed to be influenced by genetic factors, infections, and immune dysregulation. Current studies indicate that neutrophils and macrophages play crucial roles in the pathogenesis of Still's disease, along with involvement of natural killer cells, T cells, and B cells. Advances in biologic agents have expanded treatment strategies beyond conventional approaches, with cytokine-targeted agents showing promise in the management of Still's disease. Some cytokine-targeting biologic agents can be developed based on clinical manifestations, complications, immune cells, and molecular networks. Emphasis of immunophenotyping for precise clinical subtyping and targeted molecular therapies based on these findings is crucial for optimising treatment outcomes. In this Review, we discuss the latest advancements in the understanding of Still's disease pathogenesis and corresponding therapeutic approaches.

斯蒂尔病是一种具有典型多基因遗传背景的系统性自身炎症性疾病,其特征是多关节炎、高热、鲑鱼状皮疹和高铁蛋白血症。尽管 Still's 病的确切病因仍不清楚,但据信它受到遗传因素、感染和免疫失调的影响。目前的研究表明,中性粒细胞和巨噬细胞在 Still's 病的发病机制中起着关键作用,自然杀伤细胞、T 细胞和 B 细胞也参与其中。生物制剂的进步使治疗策略超越了传统方法,细胞因子靶向制剂在治疗斯蒂尔病方面大有可为。一些细胞因子靶向生物制剂可根据临床表现、并发症、免疫细胞和分子网络进行开发。强调通过免疫分型进行精确的临床亚型分析,并根据这些发现进行有针对性的分子治疗,对于优化治疗效果至关重要。在本综述中,我们将讨论在了解斯蒂尔病发病机制和相应治疗方法方面取得的最新进展。
{"title":"Advancing personalised precision treatment for Still's disease based on molecular characteristics and disease progression.","authors":"Yujie Shen, Jinchao Jia, Jialin Teng, Chengde Yang, Qiongyi Hu","doi":"10.1016/S2665-9913(24)00225-X","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00225-X","url":null,"abstract":"<p><p>Still's disease, a systemic autoinflammatory disorder with a classic multigenetic background, is characterised by polyarthritis, high-spiking fever, salmon-like evanescent skin rash, and hyperferritinaemia. Although the exact cause of Still's disease remains unclear, it is believed to be influenced by genetic factors, infections, and immune dysregulation. Current studies indicate that neutrophils and macrophages play crucial roles in the pathogenesis of Still's disease, along with involvement of natural killer cells, T cells, and B cells. Advances in biologic agents have expanded treatment strategies beyond conventional approaches, with cytokine-targeted agents showing promise in the management of Still's disease. Some cytokine-targeting biologic agents can be developed based on clinical manifestations, complications, immune cells, and molecular networks. Emphasis of immunophenotyping for precise clinical subtyping and targeted molecular therapies based on these findings is crucial for optimising treatment outcomes. In this Review, we discuss the latest advancements in the understanding of Still's disease pathogenesis and corresponding therapeutic approaches.</p>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study. 英国英格兰和威尔士服务不足的类风湿关节炎患者群体开始使用生物和靶向合成修饰疾病抗风湿药物的相关因素:一项全国队列研究。
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-10-15 DOI: 10.1016/S2665-9913(24)00221-2
Mark D Russell, Mark Gibson, Benjamin Zuckerman, Kanta Kumar, Shirish Dubey, Maryam A Adas, Edward Alveyn, Samir Patel, Zijing Yang, Katie Bechman, Elizabeth Price, Sarah Gallagher, Andrew P Cope, Sam Norton, James B Galloway
<p><strong>Background: </strong>Quantifying health-care inequality is essential to addressing the imbalance in outcomes attributable to age, sex, race or ethnicity, and multimorbidity. In this study, we analysed differences in the initiation of biological or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis within the universal health-care system of England and Wales, UK.</p><p><strong>Methods: </strong>An observational cohort study was conducted using the National Early Inflammatory Arthritis Audit (NEIAA) dataset. We included all patients with rheumatoid arthritis who were enrolled in NEIAA between May 8, 2018, and April 30, 2022, and who had 12-month follow-up data available. Modified Poisson regression was used to explore factors associated with the initiation of biological and targeted synthetic DMARDs within 12 months of initial rheumatology assessment. The factors evaluated included age, sex, ethnicity, socioeconomic status (index of multiple deprivation), smoking status, and relevant comorbidities (lung disease, cardiovascular disease, cancer, and depression). NEIAA is supported by people with lived experience of rheumatoid arthritis, who contributed to study design and the interpretation of findings.</p><p><strong>Findings: </strong>6098 patients in NEIAA had new diagnoses of rheumatoid arthritis and available follow-up data. The mean age was 59·2 years (SD 14·9); 3912 (64·2%) patients were women and 2186 (35·8%) were men. 6047 (99·2%) patients had available ethnicity data, of whom 5215 (86·2%) were White, 152 (2·5%) were Black, 478 (7·9%) were Asian, and 202 (3·3%) were of mixed or other ethnicities. 508 (8·3%) of 6098 patients initiated biological and targeted synthetic DMARDs within 12 months. Patients younger than 40 years were more likely to be initiated on biological and targeted synthetic DMARDs than individuals older than 65 years (multivariable-adjusted risk ratio 2·41 [95% CI 1·83-3·19]; p<0·0001). Asian individuals were less likely to be initiated on biological and targeted synthetic DMARDs than White individuals (0·52 [0·36-0·76]; p=0·0007), which persisted after adjustment for socioeconomic status, comorbidities, baseline disease severity, and the initial response to conventional synthetic DMARDs. These differences were evident for Asian women but not Asian men. Black individuals were more likely to be initiated on biological and targeted synthetic DMARDs than White individuals (1·54 [1·10-2·16]; p=0·012), which became non-significant after adjusting for baseline disease severity and autoantibody status.</p><p><strong>Interpretation: </strong>The initiation of biological and targeted synthetic DMARDs for patients with newly diagnosed rheumatoid arthritis varies markedly by ethnicity and age in the universal health-care system of England and Wales. This study demonstrates the importance of providing tailored information and ensuring equitable access to high-quality care fo
背景:量化医疗保健的不平等对于解决因年龄、性别、种族或民族以及多病导致的结果不平衡问题至关重要。在这项研究中,我们分析了英国英格兰和威尔士全民医疗系统中类风湿性关节炎患者开始使用生物或靶向合成改良抗风湿药物(DMARDs)的差异:利用全国早期炎症性关节炎审计(NEIAA)数据集开展了一项观察性队列研究。我们纳入了所有在2018年5月8日至2022年4月30日期间加入NEIAA且有12个月随访数据的类风湿关节炎患者。我们采用了修正泊松回归法来探讨与初次风湿病学评估后 12 个月内开始使用生物和靶向合成 DMARDs 相关的因素。评估的因素包括年龄、性别、种族、社会经济状况(多重贫困指数)、吸烟状况和相关合并症(肺病、心血管疾病、癌症和抑郁症)。NEIAA 得到了类风湿关节炎患者的支持,他们参与了研究设计和结果解释:在 NEIAA 的 6098 名患者中,有新确诊的类风湿关节炎患者和可用的随访数据。平均年龄为 59-2 岁(SD 14-9);3912 名(64-2%)患者为女性,2186 名(35-8%)患者为男性。6047名(99-2%)患者有可用的种族数据,其中5215名(86-2%)为白人,152名(2-5%)为黑人,478名(7-9%)为亚洲人,202名(3-3%)为混血或其他种族。6098名患者中有508人(8-3%)在12个月内开始使用生物和靶向合成DMARDs。与 65 岁以上的患者相比,40 岁以下的患者更有可能开始使用生物和靶向合成 DMARDs(多变量调整风险比为 2-41 [95% CI 1-83-3-19];P解释:在英格兰和威尔士的全民医疗保健系统中,新确诊类风湿关节炎患者开始使用生物和靶向合成DMARDs的情况因种族和年龄的不同而存在明显差异。这项研究表明,为医疗服务不足的患者群体提供量身定制的信息并确保其公平获得高质量的医疗服务非常重要。如果要有效缓解健康差异,就必须重新考虑 "一刀切 "的方法:英国山德士公司。
{"title":"Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study.","authors":"Mark D Russell, Mark Gibson, Benjamin Zuckerman, Kanta Kumar, Shirish Dubey, Maryam A Adas, Edward Alveyn, Samir Patel, Zijing Yang, Katie Bechman, Elizabeth Price, Sarah Gallagher, Andrew P Cope, Sam Norton, James B Galloway","doi":"10.1016/S2665-9913(24)00221-2","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00221-2","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Quantifying health-care inequality is essential to addressing the imbalance in outcomes attributable to age, sex, race or ethnicity, and multimorbidity. In this study, we analysed differences in the initiation of biological or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis within the universal health-care system of England and Wales, UK.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;An observational cohort study was conducted using the National Early Inflammatory Arthritis Audit (NEIAA) dataset. We included all patients with rheumatoid arthritis who were enrolled in NEIAA between May 8, 2018, and April 30, 2022, and who had 12-month follow-up data available. Modified Poisson regression was used to explore factors associated with the initiation of biological and targeted synthetic DMARDs within 12 months of initial rheumatology assessment. The factors evaluated included age, sex, ethnicity, socioeconomic status (index of multiple deprivation), smoking status, and relevant comorbidities (lung disease, cardiovascular disease, cancer, and depression). NEIAA is supported by people with lived experience of rheumatoid arthritis, who contributed to study design and the interpretation of findings.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;6098 patients in NEIAA had new diagnoses of rheumatoid arthritis and available follow-up data. The mean age was 59·2 years (SD 14·9); 3912 (64·2%) patients were women and 2186 (35·8%) were men. 6047 (99·2%) patients had available ethnicity data, of whom 5215 (86·2%) were White, 152 (2·5%) were Black, 478 (7·9%) were Asian, and 202 (3·3%) were of mixed or other ethnicities. 508 (8·3%) of 6098 patients initiated biological and targeted synthetic DMARDs within 12 months. Patients younger than 40 years were more likely to be initiated on biological and targeted synthetic DMARDs than individuals older than 65 years (multivariable-adjusted risk ratio 2·41 [95% CI 1·83-3·19]; p&lt;0·0001). Asian individuals were less likely to be initiated on biological and targeted synthetic DMARDs than White individuals (0·52 [0·36-0·76]; p=0·0007), which persisted after adjustment for socioeconomic status, comorbidities, baseline disease severity, and the initial response to conventional synthetic DMARDs. These differences were evident for Asian women but not Asian men. Black individuals were more likely to be initiated on biological and targeted synthetic DMARDs than White individuals (1·54 [1·10-2·16]; p=0·012), which became non-significant after adjusting for baseline disease severity and autoantibody status.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interpretation: &lt;/strong&gt;The initiation of biological and targeted synthetic DMARDs for patients with newly diagnosed rheumatoid arthritis varies markedly by ethnicity and age in the universal health-care system of England and Wales. This study demonstrates the importance of providing tailored information and ensuring equitable access to high-quality care fo","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Rheumatol 2024; published Online Sept 18, 2024. https://doi.org/10.1016/S2665-9913(24)00220-0. https://doi.org/10.1016/S2665-9913(24)00220-0.
IF 15 1区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-10-15 DOI: 10.1016/S2665-9913(24)00313-8
{"title":"Correction to Lancet Rheumatol 2024; published Online Sept 18, 2024. https://doi.org/10.1016/S2665-9913(24)00220-0.","authors":"","doi":"10.1016/S2665-9913(24)00313-8","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00313-8","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Rheumatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1